Company intelligence / Profile preview

Hinge Bio, Inc.

Burlingame, California, United Stateshingebio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead candidate HB2198 has shown pre-clinical in vivo results with deeper and more rapid B cell depletion than other antibody-based therapies. The goal is immune system reset via rapid and deep B cell depletion in both peripheral blood and lymphoid tissues. Clinical trials are planned for Lupus patients starting in or after mid/late 2025. No clinical data yet available.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Multivalent antibody-based therapeutics (GEM-DIMER™ platform)Multispecific antibodiesCooperative binding biologics
Industry: Biotech

Drug pipeline

1 asset

HB2198

Partnerships

Not specified; company notes interest from pharmaceutical partners [2].

Beyond the preview

Go deeper on Hinge Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hinge Bio, Inc..

Explore the full profile